Left Menu
Development News Edition

AstraZeneca COVID-19 vaccine study paused after one illness

In a statement issued on Tuesday evening, the company said its "standard review process triggered a pause to vaccination to allow review of safety data". AstraZeneca didn't reveal any information about the possible side effect except to call it "a potentially unexplained illness".

PTI | Newyork | Updated: 09-09-2020 05:45 IST | Created: 09-09-2020 05:45 IST
AstraZeneca COVID-19 vaccine study paused after one illness

Late-stage studies of AstraZeneca's COVID-19 vaccine candidate are on temporary hold while the company investigates whether a recipient's "potentially unexplained" illness is a side effect of the shot. In a statement issued on Tuesday evening, the company said its "standard review process triggered a pause to vaccination to allow review of safety data".

AstraZeneca didn't reveal any information about the possible side effect except to call it "a potentially unexplained illness". The health news site STAT first reported the pause in testing, saying the possible side effect occurred in the United Kingdom. An AstraZeneca spokesperson confirmed the pause in vaccinations covers studies in the US and other countries.

Late last month, AstraZeneca began recruiting 30,000 people in the US for its largest study of the vaccine. It also is testing the vaccine, developed by Oxford University, in thousands of people in Britain, and in smaller studies in Brazil and South Africa. Two other vaccines are in huge, final-stage tests in the United States, one made by Moderna Inc. and the other by Pfizer and Germany's BioNTech. Those two vaccines work differently than AstraZeneca's, and the studies already have recruited about two-thirds of the needed volunteers.

Temporary holds of large medical studies aren't unusual, and investigating any serious or unexpected reaction is a mandatory part of safety testing. AstraZeneca pointed out that it's possible the problem could be a coincidence; illnesses of all sorts could arise in studies of thousands of people. "We are working to expedite the review of the single event to minimize any potential impact on the trial timeline," the company statement said.

It's likely the unexplained illness was serious enough to require hospitalization and not a mild side effect such as fever or muscle pain, said Deborah Fuller, a University of Washington researcher who is working on a different COVID-19 vaccine that has not yet started human testing. "This is not something to be alarmed about," Fuller said. Instead, it's reassuring that the company is pausing the study to figure out what's happening and carefully monitoring the health of study participants.

Dr Ashish Jha of Brown University said via Twitter that the significance of the interruption was unclear but that he was "still optimistic" that an effective vaccine will be found in the coming months. "But optimism isn't evidence," he wrote. "Let's let science drive this process." Angela Rasmussen, a virologist at Columbia University in New York, tweeted that the illness may be unrelated to the vaccine, "but the important part is that this is why we do trials before rolling out a vaccine to the general public".

During the third and final stage of testing, researchers look for any signs of possible side effects that may have gone undetected in earlier patient research. Because of their large size, the studies are considered the most important study phase for picking up less common side effects and establishing safety. The trials also assess effectiveness by tracking who gets sick and who doesn't between patients getting the vaccine and those receiving a dummy shot.

The development came the same day that AstraZeneca and eight other drugmakers issued an unusual pledge, vowing to uphold the highest ethical and scientific standards in developing their vaccines. The announcement follows worries that President Donald Trump will pressure the US Food and Drug Administration to approve a vaccine before it's proven to be safe and effective.

The US has invested billions of dollars in efforts to quickly develop multiple vaccines against COVID-19. But public fears that a vaccine is unsafe or ineffective could be disastrous, derailing the effort to vaccinate millions of Americans. Representatives for the FDA did not immediately respond to requests for comment Tuesday evening.

AstraZeneca's US-traded shares fell more than 6 per cent in after-hours trading following reports of the trial being paused..


TRENDING

OPINION / BLOG / INTERVIEW

New farm bills in India: Focusing on farms or farmers?

... ...

Kenya’s COVID-19 response: Chaos amid lack of information

Confusing numbers and scanty information on how effective curfews and lockdowns have been in breaking transmission have amplified coordination and planning challenges in Kenyas response to COVID-19. Without accurate data, it is impossible t...

Farkhad Akhmedov: Calculating the price of impunity from the law

In insistences such as the battle over the Luna, Akhmedov has resorted to extreme legal machinations to subvert the High Courts decision and keep his assets from being seized. ...

Guinea’s elections hearken back to the autocracy and violence of its past

... ...

Videos

Latest News

Newly discovered hull damage not to blame for 1994 ferry disaster, report says

An Estonian ferry disaster that killed 852 people in 1994 was probably not caused by hull damage to the vessel that was first revealed in a documentary this year, experts concluded after a preliminary investigation of the video footage. The...

Rajan cautions against import substitution

Former Reserve Bank governor Raghuram Rajan on Wednesday cautioned against import substitution under the Aatmanirbhar Bharat initiative of the government, saying the country has gone down this route earlier but could not succeed. If the ...

Shah speaks to Sonowal about the situation along Assam-Mizoram border

Union Home Minister Amit Shah called Assam Chief Minister Sarbananda Sonowal on Wednesday and took stock of the recent situation along the Assam-Mizoram border following the October 17 clash in which several persons were injured, a CMO spok...

Monsanto loses final appeal over French farmer's weedkiller accident

Bayers Monsanto division on Wednesday lost a final appeal in a long-running French legal battle in which the crop chemical maker has been held liable for the accidental inhalation of a weedkiller by a crop farmer. Monsanto had been trying t...

Give Feedback